The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Systematic Drug Repositioning Based on Clinical Side-Effects
Open accessAbstract
Drug repositioning helps fully explore indications for marketed drugs and clinical candidates. Here we show that the clinical side-effects (SEs) provide a human phenotypic profile for the drug, and this profile can suggest additional disease indications. We extracted 3,175 SE-disease relationships by combining the SE-drug relationships from drug labels and the drug-disease relationships from PharmGKB. Many relationships provide explicit repositioning hypotheses, such as drugs causing hypoglycemia are potential candidates for diabetes. We built Naïve Bayes models to predict indications for 145 diseases using the SEs as features. The AUC was above 0.8 in 92% of these models. The method was extended to predict indications for clinical compounds, 36% of the models achieved AUC above 0.7. This suggests that closer attention should be paid to the SEs observed in trials not just to evaluate the harmful effects, but also to rationally explore the repositioning potential based on this "clinical phenotypic assay".
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The WEKA data mining software: an update
Hall, M., Frank, E., Holmes, G., Pfahringer, B., Reutemann, P., & Witten, I. H. (2009) · ACM SIGKDD Explorations Newsletter · doi:10.1145/1656274.1656278 · Cited by 17,750
Cytoscape 2.8: new features for data integration and network visualization
Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P.-L., & Ideker, T. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btq675 · Cited by 4,830
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Drug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248
PREDICT: a method for inferring novel drug indications with application to personalized medicine
Gottlieb, A., Stein, G. Y., Ruppin, E., & Sharan, R. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.26 · Cited by 881
Discovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816
Cytoscape 2.8: new features for data integration and network
Smoot, E., Ono, K., Ruscheinski, J., Wang, P., & Ideker, T. E. (2011) · Cited by 791
Use of ramipril in preventing stroke: double blind randomised trial
Bosch, J., Yusuf, S., Pogue, J., Sleight, P., Lonn, E., Rangoonwala, B., Davies, R., Ostergren, J., & Probstfield, J. (2002) · BMJ · doi:10.1136/bmj.324.7339.699 · Cited by 420
Cited by
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
Data-driven prediction of drug effects and interactions
Tatonetti, N. P., Ye, P. P., Daneshjou, R., & Altman, R. B. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003377 · Cited by 936
A survey of current trends in computational drug repositioning
Li, J., Zheng, S., Chen, B., Butte, A. J., Swamidass, S. J., & Lu, Z. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv020 · Cited by 555
Drug repurposing from the perspective of pharmaceutical companies
Cha, Y., Erez, T., Reynolds, I. J., Kumar, D., Ross, J., Koytiger, G., Kusko, R., Zeskind, B., Risso, S., Kagan, E., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13798 · Cited by 429
Jin, G., & Wong, S. T. C. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.005 · Cited by 416
Predicting drug–disease associations through layer attention graph convolutional network
Yu, Z., Huang, F., Zhao, X., Xiao, W., & Zhang, W. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa243 · Cited by 416
Jarada, T. N., Rokne, J. G., & Alhajj, R. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00450-7 · Cited by 384
Computational Drug Repositioning: From Data to Therapeutics
Hurle, M. R., Yang, L., Xie, Q., Rajpal, D. K., Sanseau, P., & Agarwal, P. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.1 · Cited by 373
Self-citationJahchan, N. S., Dudley, J. T., Mazur, P. K., Flores, N., Yang, D., Palmerton, A., Zmoos, A.-F., Vaka, D., Tran, K. Q. T., Zhou, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0183 · Cited by 358
Drug repositioning by integrating target information through a heterogeneous network model
Wang, W., Yang, S., Zhang, X., & Li, J. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu403 · Cited by 335
In silico methods for drug repurposing and pharmacology
Hodos, R. A., Kidd, B. A., Shameer, K., Readhead, B. P., & Dudley, J. T. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1337 · Cited by 326
Predicting drug-disease associations by using similarity constrained matrix factorization
Zhang, W., Yue, X., Lin, W., Wu, W., Liu, R., Huang, F., & Liu, F. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2220-4 · Cited by 303
Applications of Connectivity Map in drug discovery and development
Qu, X. A., & Rajpal, D. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.017 · Cited by 235
Design of efficient computational workflows for in silico drug repurposing
Vanhaelen, Q., Mamoshina, P., Aliper, A. M., Artemov, A., Lezhnina, K., Ozerov, I., Labat, I., & Zhavoronkov, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.019 · Cited by 150
Drug repositioning for Alzheimer’s disease based on systematic “omics” data mining
Zhang, M., Schmitt-Ulms, G., Sato, C., Xi, Z., Zhang, Y., Zhou, Y., St George-Hyslop, P., & Rogaeva, E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0168812 · Cited by 108
Systematic prediction of drug combinations based on clinical side-effects
Huang, H., Zhang, P., Qu, X. A., Sanseau, P., & Yang, L. (2014) · Scientific Reports · doi:10.1038/srep07160 · Cited by 73
Self-citationA Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer’s Disease
Lee, S. Y., Song, M.-Y., Kim, D., Park, C., Park, D. K., Kim, D. G., Yoo, J. S., & Kim, Y. H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01653 · Cited by 32
“…as comparison of gene expression pro fi les between a disease model and the drug-treated condition (Chen et al., 2017), network integration (Luo et al., 2017), prediction of drug-protein interactions (Yang and Agarwal, 2011), and utilization of genotype-phenotype associations (Zhang et al., 2016).”
Background
Metadata
- Authors
- Yang, L., & Agarwal, P.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-12-21
- Volume
- 6
- Issue
- 12
- Pages
- e28025
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2020132970
- Cited by
- 266
- References
- 43
- FWCI
- 12.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.